1. HBW Insight
  2. >>Health
  3. >>Policy & Regulation
  4. >>Regulation

OTC Naloxone In US Could Limit Access Due To Costs, Comments On Emergent Switch NDA Argue

 
• By Malcolm Spicer

American Society of Anesthesiologists and attorney Scott Lassman say in comments submitted to docket for meeting of FDA’s Nonprescription Drug and Anesthetic and Analgesic Drug Products they disagree with agency’s suggestion studies showing all naloxone products in all delivery formats can be used safely OTC point to all the products moving to nonprescription.

• Source: Shutterstock

Making all naloxone products available OTC in the US could limit, not expand access to the opioid overdose treatment, according to comments submitted before a panel of Food and Drug Administration advisors discusses the first naloxone switch proposal, for a nasal spray.

The American Society of Anestiologists and attorney Scott Lassman both made clear in comments, submitted to the docket for a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

Kenvue Adds Vaping Cessation Indication To Nicorette QuickMist In Australia

 
• By David Ridley

Kenvue's Nicorette QuickMist becomes the first product in Australia to be approved by the Therapeutic Goods Administration (TGA) for the treatment of nicotine vaping dependence.

US FDA Maintaining Approval Output Despite Losing Staff

 
• By Derrick Gingery

Reviewers were not targeted by the FDA reduction in force, but increasing attrition and difficulties hiring new staff still do not seem to have impacted new and generic drug approval totals.

German Quaternary Wastewater Treatment Cost Estimates ‘Not Realistic’

 
• By David Ridley

Updating wastewater treatment facilities in Germany will cost almost three times more than the German Association of Local Public Utilities (VKU) has predicted, according to a Pharma Deutschland analysis.

New US FDA CDER Director Pledges No Politics In Approvals, Adds Higher Ups Can Overturn

 
• By Sarah Karlin-Smith

New CDER Director George Tidmarsh promised to keep politics out of drug approvals, but suggested during a meeting with staff that he could not insulate the drug center from political pressures coming from those above him.

More from Policy & Regulation

Combat Meth Act PSE Daily Purchase Limit Once Too High For States Now Embraced By Most

 
• By Malcolm Spicer

Limits so effective that states are relaxing restrictions they previously set exceeding the nationwide limit Congress imposed in Combat Meth Act in 2006 on the amount of PSE, as well as a second meth precursor, ephedrine, in OTC drugs consumers can purchase daily.

New US FDA CDER Director Pledges No Politics In Approvals, Adds Higher Ups Can Overturn

 
• By Sarah Karlin-Smith

New CDER Director George Tidmarsh promised to keep politics out of drug approvals, but suggested during a meeting with staff that he could not insulate the drug center from political pressures coming from those above him.

FDA Whips Up Sunscreen Delivery Format Warnings To Firms In US, Israel, Sweden

FDA admonishes five marketers for straying from approved sunscreen dosage forms in recent warning letters. Violative delivery formats render products unapproved drugs and misbranded.